» Articles » PMID: 15790588

Deregulated Expression of the PER1, PER2 and PER3 Genes in Breast Cancers

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2005 Mar 26
PMID 15790588
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Disruption of circadian rhythm may be a risk factor in the development of breast cancer, but molecular changes in circadian rhythm controlled genes in breast cancer cells are still unexplored. We used immunohistochemical staining, methylation specific PCR and direct sequencing methods to analyze molecular changes in three most important genes, namely PER1, PER2 and PER3, in circadian rhythm in 55 cases of breast cancer of Taiwanese women. Our results reveal disturbances in the expression of the three period (PER) genes in most (>95%) of the breast cancerous cells in comparison with the nearby non-cancerous cells. The PER gene deregulation is not caused by genetic mutations but most probably by methylation of the PER1 or PER2 promoter. Methylation of the PER gene promoters has a strong correlation with c-erbB2 expression (P = 0.017). Since the circadian clock controls expression of cell-cycle related genes, we suggest that disturbances in PER gene expression may result in disruption of the control of the normal circadian clock, thus benefiting the survival of cancer cells and promoting carcinogenesis. Differential expression of circadian genes in non-cancerous and cancerous cells may provide a molecular basis for chronotherapy of breast cancer.

Citing Articles

PER3 suppresses tumor metastasis of oral squamous cell carcinoma by promoting HIF-1α degradation.

Li Y, Li B, Yang K, Zhu L, Tang H, Huang Y Transl Oncol. 2024; 52():102258.

PMID: 39733745 PMC: 11743850. DOI: 10.1016/j.tranon.2024.102258.


Road traffic noise and breast cancer: DNA methylation in four core circadian genes.

Thacher J, Snigireva A, Dauter U, Delaval M, Oudin A, Mattisson K Clin Epigenetics. 2024; 16(1):168.

PMID: 39587706 PMC: 11590349. DOI: 10.1186/s13148-024-01774-z.


Circadian rhythms and breast cancer: from molecular level to therapeutic advancements.

Li D, Zhou T, Gao J, Wu G, Yang G J Cancer Res Clin Oncol. 2024; 150(9):419.

PMID: 39266868 PMC: 11393214. DOI: 10.1007/s00432-024-05917-w.


The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression.

Liu D, Wei B, Liang L, Sheng Y, Sun S, Sun X Cancer Res. 2024; 84(14):2265-2281.

PMID: 38718296 PMC: 11247325. DOI: 10.1158/0008-5472.CAN-23-3942.


Unraveling the role of the circadian clock genes in cervical squamous cell carcinoma and endocervical adenocarcinoma: A prognostic indicator for prognostic, immunotherapy response, and chemotherapy sensitivity.

Xu J, Huang X, Gou S, Luo H, Zeng S, Zhang Q J Cancer. 2024; 15(9):2788-2804.

PMID: 38577592 PMC: 10988312. DOI: 10.7150/jca.94063.